Payment overview · 2025
General Payments
$519.12
25 reported records · 15 companies
Healthcare provider profile · identity verified
Keith D Shealy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, SC · NPI 1578557153
Verified facts
What the public records show
CMS Open Payments records show Keith D Shealy, M.D. received $519.12 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.74 | 12.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.40 | 10.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.14 | 9.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.53 | 9.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.99 | 8.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.78 | 8.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.13 | 6.8% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $29.90 | 5.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.72 | 5.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.49 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.40 | 4.5% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $19.23 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.14 | 3.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.79 | 3.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.74 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $519.12 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.74 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.14 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.27 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.27 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.27 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 188 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 760 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 154 |
| Omeprazole | Omeprazole | 482 | 130 |
| Lisinopril | Lisinopril | 391 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 98 |
| Metformin Hcl | Metformin Hcl | 342 | 101 |
| Potassium Chloride | Potassium Chloride | 292 | 95 |
| Losartan Potassium | Losartan Potassium | 288 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 87 |
| Trazodone Hcl | Trazodone Hcl | 263 | 106 |
| Gabapentin | Gabapentin | 250 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 228 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 73 |
| Furosemide | Furosemide | 202 | 75 |
| Eliquis | Apixaban | 188 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 51 |
| Alendronate Sodium | Alendronate Sodium | 149 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 149 | 53 |
| Meloxicam | Meloxicam | 143 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 20 |
| Montelukast Sodium | Montelukast Sodium | 109 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 29 |
| Famotidine | Famotidine | 101 | 33 |
| Allopurinol | Allopurinol | 99 | 27 |
| Sertraline Hcl | Sertraline Hcl | 95 | 37 |
| Tramadol Hcl | Tramadol Hcl | 95 | 32 |
| Finasteride | Finasteride | 89 | 27 |
| Metformin Hcl Er | Metformin Hcl | 88 | 24 |
| Simvastatin | Simvastatin | 86 | 19 |
| Carvedilol | Carvedilol | 80 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 27 |
| Valsartan | Valsartan | 79 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 25 |
| Klor-Con M20 | Potassium Chloride | 73 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 66 |
| Donepezil Hcl | Donepezil Hcl | 66 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 21 |
| Alprazolam | Alprazolam | 60 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 18 |
| Meclizine Hcl | Meclizine Hcl | 59 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 19 |
| Ozempic | Semaglutide | 56 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 18 |
| Lamotrigine | Lamotrigine | 53 | 12 |
| Warfarin Sodium | Warfarin Sodium | 52 | 12 |
| Glipizide Er | Glipizide | 51 | 20 |
| Ibuprofen | Ibuprofen | 51 | 23 |
| Buspirone Hcl | Buspirone Hcl | 50 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 20 |
| Celecoxib | Celecoxib | 49 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 13 |
| Atenolol | Atenolol | 48 | 16 |
| Nifedipine Er | Nifedipine | 48 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 16 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Linzess | Linaclotide | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 16 |
| Prednisone | Prednisone | 41 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 15 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Estradiol | Estradiol | 38 | 12 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 13 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 12 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | suppressed |
| Nystatin | Nystatin | 34 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 30 |
| Synthroid | Levothyroxine Sodium | 33 | 12 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 28 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | 15 |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 12 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 11 |
| Naproxen | Naproxen | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | 12 |
| Azithromycin | Azithromycin | 18 | 16 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $519.12 · 25 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, CeQur Simplicity, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error